139 related articles for article (PubMed ID: 15350365)
1. Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Terao T
Gynecol Oncol; 2004 Sep; 94(3):725-34. PubMed ID: 15350365
[TBL] [Abstract][Full Text] [Related]
2. Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Yamakawa T; Morishita H; Terao T
Cancer; 2003 Jul; 98(2):424-30. PubMed ID: 12872365
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
4. Plasma bikunin as a favorable prognostic factor in ovarian cancer.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
J Clin Oncol; 2005 Mar; 23(7):1463-72. PubMed ID: 15735122
[TBL] [Abstract][Full Text] [Related]
5. The protease inhibitor bikunin, a novel anti-metastatic agent.
Kobayashi H; Suzuki M; Hirashima Y; Terao T
Biol Chem; 2003 May; 384(5):749-54. PubMed ID: 12817471
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of KAI1 metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer.
Schindl M; Birner P; Breitenecker G; Oberhuber G
Gynecol Oncol; 2001 Nov; 83(2):244-8. PubMed ID: 11606078
[TBL] [Abstract][Full Text] [Related]
7. Reduced syndecan-1 expression stimulates heparin-binding growth factor-mediated invasion in ovarian cancer cells in a urokinase-independent mechanism.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
Oncol Rep; 2005 Aug; 14(2):449-57. PubMed ID: 16012729
[TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
9. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
10. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
[TBL] [Abstract][Full Text] [Related]
11. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
[TBL] [Abstract][Full Text] [Related]
12. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor- alpha and interleukin-1 beta in macrophages.
Wakahara K; Kobayashi H; Yagyu T; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
J Infect Dis; 2005 Mar; 191(6):930-8. PubMed ID: 15717269
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer.
Kobayashi H; Yagyu T; Inagaki K; Kondo T; Suzuki M; Kanayama N; Terao T
Cancer; 2004 Feb; 100(4):869-77. PubMed ID: 14770446
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
15. Could high plasma bikunin predict a favorable outcome in ovarian cancer?
McIntosh M
Nat Clin Pract Oncol; 2005 Oct; 2(10):502-3. PubMed ID: 16205769
[No Abstract] [Full Text] [Related]
16. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
[TBL] [Abstract][Full Text] [Related]
17. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
Nakamura K; Abarzua F; Kodama J; Hongo A; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2009 Feb; 34(2):345-53. PubMed ID: 19148468
[TBL] [Abstract][Full Text] [Related]
18. A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade.
Kobayashi H; Suzuki M; Tanaka Y; Kanayama N; Terao T
J Biol Chem; 2003 Mar; 278(10):7790-9. PubMed ID: 12496270
[TBL] [Abstract][Full Text] [Related]
19. A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
Kobayashi H; Suzuki M; Kanayama N; Terao T
Clin Exp Metastasis; 2004; 21(2):159-66. PubMed ID: 15168733
[TBL] [Abstract][Full Text] [Related]
20. Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Terao T
Hum Pathol; 2002 Nov; 33(11):1105-13. PubMed ID: 12454815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
